Product information: Active name: LANDIOLOL HYDROCHLORIDE Brand name: RAPIBLYK Innovator name AOP ORPHAN PHARMACEUTICALS AG Approval Date: NOV 22, 2024 Therapeutic activity: LANDIOLOL HYDROCHLORIDE is indicated for the treatment of ultra-short-acting β1-selective blocking agent. It inhibits the positive chronotropic effects of catecholamine adrenaline and norepinephrine on the heart. Route of administration Powder, Intravenous Structure […]
Iodine based contrasting agent: IOMEPROL
IOMEPROL: Active name: IOMEPROL Brand name: IOMERVU Innovator name BRACCO DIAGNOSTICS INC Approval Date: NOV 27, 2024 Therapeutic activity: Tri-iodinated X-Ray contrasting agent. Iomeprol has been investigated for the diagnostic of Coronary Artery Disease. Route of administration Intra arterial/intravenous, Injection Structure Chemical name N,N’-bis(2,3-dihydroxypropyl)-5-[(hydroxyacetyl)- methylamino]-2,4,6-tri-iodo-1,3-benzenedicarboxamide. CAS 78649-41-9 Dosage Available in four iodine concentration. 510 […]
ALK Rearranged lung cancer: Ensartinib
Active name: ENSARTINIB HYDROCHLORIDE Brand name: ENSACOVE Innovator name XCOVERY HOLDINGS INC Approval Date: Dec 18, 2024 Therapeutic activity: ENSACOVE is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). Route of administration Capsule, oral Structure Chemical name 6-amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-N-{4-[(3R,5S)- 3,5-dimethylpiperazine-1-carbonyl]phenyl}pyridazine-3-carboxamide, dihydrochloride CAS […]
Treatment of cystic fibrosis: Vanzacaftor
Active name: Vanzacaftor calcium dihydrate Brand name: ALYFTREK Innovator name VERTEX PHARMACEUTICALS INC Approval Date: Dec 20, 2024 Therapeutic activity: Binds to the different sites on the CFTR protein and have an additive effect in facilitating the cellular processing and trafficking of select mutant forms of CFTR (F508del-CFTR) to increase the amount of CFTR […]
FDA GRANTS ACCELERATED APPROVAL PIRTOBRUTINIB
Active name: Pirtobrutinib Brand name: Jaypirca Innovator name LOXO ONCOLOGY ING Approval Date: Jan 27, 2023 Therapeutic activity: kinase inhibitor used to treat relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy. Route of adminstration Tablet, oral Structure Chemical name 5-amino-3-{4-[(5-fluoro-2-methoxybenzamido)methyl]phenyl}-1-[(2S)- 1,1,1-trifluoropropan-2-yl]-1H-pyrazole-4-carboxamide CAS 2101700-15-4 Dosage: […]
Oral ER degrader: Elacestrant
Active name: Elacestrant dihydrochloride Brand name: Orserdu Innovator name STEMLINE THERAPEUTICS INC Approval Date: Jan 27, 2023 Therapeutic activity: Elacestrant is an estrogen receptor antagonist used to treat ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy Route of adminstration Tablet, oral Structure […]
A Potential sodium-glucose co-transporter 2 (SGLT2) inhibitor: BEXAGLIFLOZIN
Bexagliflozin basic information Active ingredient name: Bexagliflozin Brand name: Brenzavvy, Bexacat (Veterinary) Innovator name THERACOSBIO LLC Approval Date: Jan 20, 2023 Therapeutic activity: Highly specific and potent sodium-glucose co-transporter 2 (SGLT2) inhibitor. SGLT2 is responsible for 60% to 90% of renal glucose re-uptake, and unlike other isoforms such as SGLT1, SGLT2 is mainly […]
